Skip to main content

Advertisement

Table 2 Demographic data, exposure characteristics, and lung function tests according to latency period

From: The association of human leukocyte antigen polymorphisms with disease severity and latency period in patients with silicosis

  Short latency** Long latency*** P Mean
Subjects n 23 25 - -
Age (years) 22.4 ± 7.2 23.4 ± 8.5 - NS*
BMI 21.7 ± 3.1 22.6 ± 2.6 - NS*
Total exposure duration (months) 21.4 ± 13.9 38.0 ± 27.4 0.012 Significant
Latency period (months) 37.9 ± 17.6 73.0 ± 16.6 0.001 Significant
Smoking (pack/years) 3.9 ± 4.4 8.1 ± 6.5 0.014 Significant
FEV1 L 3.7 ± 0.6 3.3 ± 0.9 - NS*
FEV1% pred 95.0 ± 18.7 83.4 ± 24.6 - NS*
FVC L 4.4 ± 0.8 3.9 ± 1.0 - NS*
FVC% pred 96.6 ± 19.3 83.5 ± 25.1 0.05 Borderline
FEV1/FVC% 84.3 ± 7.3 83.1 ± 9.4 - NS*
  1. *NS, Not significant; **Short latency, cases whose latency periods are ≤ 50 months. ***Long latency, cases whose latency periods are > 50 months.